This National Institutes of Health (NIH) grant is for developing innovative strategies to precisely target and manipulate brain cell subtypes altered in aging, Alzheimer’s Disease (AD), and AD-Related Dementias (ADRDs). The purpose is to foster sophisticated tools that integrate adeno-associated virus (AAV) capsid engineering with enhancer element identification. This will enable optimal targeting of disease-relevant cells in aged mammalian brains, allowing in vivo monitoring and manipulation to address mechanistic hypotheses in animal models of brain aging and AD/ADRD. This R61/R33 Exploratory/Developmental Phased Award includes an R61 phase (up to 2 years) for proof-of-principle, transitioning to an R33 phase (up to 3 years) for implementation and hypothesis testing. Clinical trials are not allowed. The application deadline is October 07, 2024.
Opportunity ID: 354240
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AG-25-024 |
| Funding Opportunity Title: | Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 16, 2024 |
| Last Updated Date: | May 16, 2024 |
| Original Closing Date for Applications: | Oct 07, 2024 |
| Current Closing Date for Applications: | Oct 07, 2024 |
| Archive Date: | Nov 12, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses For profit organizations other than small businesses Special district governments City or township governments Native American tribal governments (Federally recognized) County governments Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Private institutions of higher education State governments Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Notice of Funding Opportunity (NOFO) invites applications proposing innovative strategies to target and manipulate brain cell subtypes that are altered in aging, Alzheimer’s Disease (AD), and AD-Related Dementias (ADRDs). ADRDs include frontotemporal disorders (FTD), Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). Specifically, the goal of the NOFO is to encourage the development and utilization of sophisticated tools that pair breakthroughs in adeno-associated virus (AAV) capsid engineering with enhancer element identification to (1) optimize precise targeting of disease-relevant cell subtypes in aged and degenerating mammalian brains and (2) monitor and/or manipulate these cells in vivo to address mechanistic hypotheses related to brain aging and AD/ADRD in animals models. To achieve this goal, the NOFO utilizes the R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for pilot activities to demonstrate proof-of-principle. The R33 phase provides up to 3 years of support for implementation activities including hypothesis testing. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-024.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 354240 Full Announcement-RFA-AG-25-024 -> RFA-AG-25-024-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00286459 | Sep 06, 2024 | Oct 07, 2024 | View |
Package 1
Mandatory forms
354240 RR_SF424_5_0-5.0.pdf
354240 PHS398_CoverPageSupplement_5_0-5.0.pdf
354240 RR_OtherProjectInfo_1_4-1.4.pdf
354240 PerformanceSite_4_0-4.0.pdf
354240 RR_KeyPersonExpanded_4_0-4.0.pdf
354240 RR_Budget10_3_0-3.0.pdf
354240 PHS398_ResearchPlan_5_0-5.0.pdf
354240 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
354240 RR_SubawardBudget10_30_3_0-3.0.pdf
354240 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
